Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Khan AM, Lin P, Kamdar N, Mahmoudi E, Latham-Mintus K, Kobayashi L, Clarke P. Location matters: the role of the neighborhood environment for incident cardiometabolic disease in adults aging with physical disability. Am J Health Promot. 2024 Jan 18. doi: 10.1177/08901171241228017
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Sheer R, Schwab P, Essex MN, Cappelleri JC, Reiners A, Bobula J, Pasquale MK. Factors related to the use of topical vs. oral NSAIDs for sprains, strains, and contusions in a senior population: a retrospective analysis of administrative claims data. Drugs Aging. 2018 Oct;35(10):937-50. doi: 10.1007/s40266-018-0585-8
Schwab P, Louder A, Li Y, Mallick R, Bays H. Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe. Drugs Aging. 2014 Sep;31(9):683-94. doi: 10.1007/s40266-014-0200-6
Lukert B, Satram-Hoang S, Wade S, Anthony MS, Gao G, Downs R. Physician differences in managing postmenopausal osteoporosis: results from the POSSIBLE US™ treatment registry study. Drugs Aging. 2011 Sep 1;28(9):713-27.
Hahn EJ, Rayens MK, Warnick TA, Chirila C, Rasnake RT, Paul TP, Christie D. A controlled trial of a quit and win contest. Am J Health Promot. 2005 Nov 1;20(2):117-26.